

IACH 2021 Scientific Program
All timing in CEST

| Friday, September 24, 2021 | |
|----------------------------|---|
| 12:45-13:00 | Welcome: Mohamad Mohty , France & Arnon Nagler , Israel |
| 13:00-14:50 | Opening Session: State of the art therapy in ... |
| 13:00-13:20 | CLL: Arnon Kater , Netherlands |
| 13:20-13:40 | CML: Giuseppe Saglio , Italy |
| 13:40-14:00 | Hodgkin lymphoma: Ali Bazarbachi , Lebanon |
| 14:00-14:20 | Mantle cell lymphoma: Remy Dulery , France |
| 14:20-14:50 | Panel Discussion |
| 14:50-15:00 | <i>Break</i> |
| 15:00-16:50 | Session 1: Immunotherapy |
| 15:00-15:20 | Immune modulation prior and post HSCT for AML: Gesine Bug , Germany |
| 15:20-15:40 | TCR Engineering: Fabio Ciceri , Italy |
| 15:40-16:00 | Anti-virus CTLs: May Daher , USA |
| 16:00-16:20 | Gamma/delta T cells: Jurgen Kuball , Netherlands |
| 16:20-16:50 | Panel Discussion |
| 16:50-17:00 | <i>Break</i> |
| 17:00-18:50 | Session 2: Transplant indications in ... |
| 17:00-17:20 | AML: Arnon Nagler , Israel |
| 17:20-17:40 | ALL: Sebastian Giebel , Poland |
| 17:40-18:00 | MF: Ibrahim Yakoub-Agha , France |
| 18:00-18:20 | MDS: Corey Cutler , USA |
| 18:20-18:50 | Panel Discussion |
| 18:50-19:00 | IACH H.J. Khoury Award Ceremony Presenters: Mohamad Mohty , France & Arnon Nagler , Israel Recipient: Enric Carreras , Spain |
| 19:00-19:30 | Keynote lecture: ALL – Progress in research and Therapy in 2021: Hagop Kantarjian , USA |
| 19:30-21:00 | The role of modern agents for relapsed/refractory myeloma CME-accredited symposium Moderators: Mohamad Mohty , France & Arnon Nagler , Israel |
| 19:30-19:40 | Introduction: latest advances in myeloma therapy: Mohamad Mohty , France |
| 19:40-19:55 | Mechanism of action of XPO inhibitors: Nizar Bahlis , Canada |
| 19:55-20:10 | The case for XPO1 inhibitors: Mohamad Mohty , France |
| 20:10-20:25 | The case for Venetoclax: Rafael Fonseca , USA |
| 20:25-20:40 | The case for Melflufen: Graham Jackson , UK |
| 20:40-21:00 | Panel Discussion |

| Saturday, September 25, 2021 | |
|------------------------------|---|
| 09:00-11:20 | Session 3: Advances in transplant complications |
| 09:00-09:20 | Acute GVHD: Iskra Pusic , USA |
| 09:20-09:40 | Chronic GVHD: Zinaida Perić , Croatia |
| 09:40-10:00 | CMV infection at the era of letermovir: Bipin Savani , USA |
| 10:00-10:20 | Endothelium-related complications: Selim Corbacioglu , Germany |
| 10:20-10:40 | EBV-PTLD: Rafael de la Cámara , Spain |
| 10:40-11:20 | Panel Discussion |
| 11:20-11:30 | <i>Break</i> |
| 11:30-13:20 | Session 4: Advances in AML therapy |
| 11:30-11:50 | The case for CPX-351: Pau Montesinos , Spain |
| 11:50-12:10 | The case for oral azacytidine: Amer Zeidan , USA |

| | |
|-------------|---|
| 12:10-12:30 | The case for venetoclax: Fahrad Ravandi , USA |
| 12:30-12:50 | The case for Flt3 inhibitors: Jordi Esteve , Spain |
| 12:50-13:20 | Panel Discussion |
| 13:20-13:30 | <i>Break</i> |
| 13:30-14:15 | Optimising the management of hepatic VOD: utilising the tools available to improve patient outcome Industry Symposium |
| 14:15-15:00 | Treating high-risk AML* in the real world <i>*High-risk AML defined as therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AMC-MRC)</i> Industry Symposium |
| 15:00-15:30 | Your questions answered live: latest real-world evidence in high-risk AML* with Professor Cluzeau <i>*High-risk AML defined as therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC)</i> Industry Meet the Expert (MTE) Session |
| 15:00-15:30 | <i>Break</i> |
| 15:30-17:20 | Session 5: Advances in rare entities |
| 15:30-15:50 | BPDCN: Naveen Pemmaraju , USA |
| 15:50-16:10 | Mastocytosis: Michael Byrne , USA |
| 16:10-16:30 | Aplastic anemia: Jakob Passweg , Switzerland |
| 16:30-16:50 | Waldenstrom disease: Meletios-Athanasios Dimopoulos , Greece |
| 16:50-17:20 | Panel Discussion |
| 17:20-17:30 | <i>Break</i> |
| 17:30-18:30 | The hard-to-treat lenalidomide relapsed/refractory patients CME-accredited symposium Moderators: Mohamad Mohty , France & Arnon Nagler , Israel |
| 17:30-17:50 | Carfilzomib-based combinations: Thomas Martin , USA |
| 17:50-18:10 | Pomalidomide-based combinations: Fredrik Schjesvold , Norway |
| 18:10-18:30 | Panel Discussion |
| 18:30-20:30 | Session 6: Bispecific antibodies and antibody-drug conjugates in ... |
| 18:30-18:50 | Lymphoma: Gilles Salles , USA |
| 18:50-19:10 | Myeloma: Salomon Manier , France |
| 19:10-19:30 | AML: Pierre Peterlin , France |
| 19:30-19:50 | ALL: Eolia Brissot , France |
| 19:50-20:30 | Panel Discussion |

Sunday, September 26, 2021

| | |
|-------------|--|
| 09:00-10:50 | Session 7: State of the art in HSCT |
| 09:00-09:20 | Optimizing stem cell collection: Christian Chabannon , France |
| 09:20-09:40 | PtCy for GVHD prophylaxis: Didier Blaise , France |
| 09:40-10:00 | Optimal choice of donor: Annalisa Ruggeri , Italy |
| 10:00-10:20 | Bloodless HSCT: Bhagirathbhai Dholaria , USA |
| 10:20-10:50 | Panel Discussion |
| 10:50-11:00 | <i>Break</i> |
| 11:00-12:00 | Latest advances in chronic GvHD CME-accredited symposium Moderators: Mohamad Mohty , France & Arnon Nagler , Israel |
| 11:00-11:20 | Diagnosis and grading of chronic GVHD: Daniel Wolff , Germany |
| 11:20-11:40 | Management of steroid refractory chronic GVHD: a focus on belumosudil: Aleksandr Lazaryan , USA |
| 11:40-12:00 | Panel Discussion |
| 12:00-13:50 | Session 8: CAR T cells in ... |
| 12:00-12:20 | ALL: Jordan Gauthier , USA |

| | |
|--------------------|---|
| 12:20-12:40 | CLL: Mohamed Kharfan-Dabaja , USA |
| 12:40-13:00 | Myeloma: Mohamad Mohty , France |
| 13:00-13:20 | Lymphoma: Anna Sureda , Spain |
| 13:20-13:50 | Panel Discussion |
| 13:50-14:00 | <i>Break</i> |
| 14:00-15:30 | Practical considerations in CAR-T therapy CME-accredited symposium Moderators: Mohamad Mohty , France & Arnon Nagler , Israel |
| 14:00-14:20 | Patient selection and timely referral: Michael Loschi , France |
| 14:20-14:40 | Safety of CAR-T cells in elderly lymphoma: Ron Ram , Israel |
| 14:40-15:00 | Prognostic features in large B-cell lymphoma patients receiving CAR T-cell therapy: Gloria Iacoboni , Spain |
| 15:00-15:30 | Panel Discussion |
| 15:30-15:45 | Closing Remarks: Mohamad Mohty , France & Arnon Nagler , Israel |